Can I read Palbociclib Demonstrates Intracranial Activity in Progressive Brain Metastases Harboring Cyclin-dependent Kinase Pathway Alterations on EtoBox?

Palbociclib Demonstrates Intracranial Activity in Progressive Brain Metastases Harboring Cyclin-dependent Kinase Pathway Alterations by Brastianos, Priscilla K. (author);Kim, Albert E. (author);Wang, Nancy (author);Lee, Eudocia Q. (author);Ligibel, Jennifer (author);Cohen, Justine V. (author);Chukwueke, Ugonma N. (author);Mahar, Maura (author);Oh, Kevin (author);White, Michael D. (author);Shih, Helen A. (author);Forst, Deborah (author);Gainor, Justin F. (author);Heist, Rebecca S. (author);Gerstner, Elizabeth R. (author);Batchelor, Tracy T. (author);Lawrence, Donald (author);Ryan, David P. (author);Iafrate, A. John (author);Giobbie-Hurder, Anita (author);Santagata, Sandro (author);Carter, Scott L. (author);Cahill, Daniel P. (author);Sullivan, Ryan J. (author) is a Medicine article available to read on EtoBox.

What is Palbociclib Demonstrates Intracranial Activity in Progressive Brain Metastases Harboring Cyclin-dependent Kinase Pathway Alterations about?

Recent studies suggest that the cyclin-dependent kinase (CDK) pathway may be a therapeutic target for brain metastases (BM). Here, we present interim analysis of a basket trial evaluating the intracranial efficacy of the CDK inhibitor palbociclib in patients with progressive BM and CDK alterations. Our study met its primary endpoint and provides evidence for performing molecular testing of archival BM tissue, if available, to inform the choice of CNS-penetrant targeted therapy. A feared complication of solid tumor malignancies is the development of BM, as this results in substantial morbidity and shortened survival. One major roadblock to the development of durable treatments is the paucity of clinical trials designed specifically to evaluate the intracranial efficacy of systemic therapies, due largely to the exclusion of patients with BM because of poor prognosis 1 . Another barrier is genomic heterogeneity between the primary tumor and BM 2,3 . This genomic divergence has important therapeutic implications, as the selection of targeted therapies for BM has traditionally relied on analysis of the primary tumor, given the ease of access to tissue outside the brain. A logical next s

Who reads Palbociclib Demonstrates Intracranial Activity in Progressive Brain Metastases Harboring Cyclin-dependent Kinase Pathway Alterations?

Author

Brastianos, Priscilla K. (author);Kim, Albert E. (author);Wang, Nancy (author);Lee, Eudocia Q. (author);Ligibel, Jennifer (author);Cohen, Justine V. (author);Chukwueke, Ugonma N. (author);Mahar, Maura (author);Oh, Kevin (author);White, Michael D. (author);Shih, Helen A. (author);Forst, Deborah (author);Gainor, Justin F. (author);Heist, Rebecca S. (author);Gerstner, Elizabeth R. (author);Batchelor, Tracy T. (author);Lawrence, Donald (author);Ryan, David P. (author);Iafrate, A. John (author);Giobbie-Hurder, Anita (author);Santagata, Sandro (author);Carter, Scott L. (author);Cahill, Daniel P. (author);Sullivan, Ryan J. (author)

Publisher

Springer Science and Business Media LLC

Published

2021

Language

EN

Field

Medicine (Life Sciences)